535 results
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
and expenses of complying with applicable securities laws and the fees and disbursements of our counsel and of our independent registered public … consultant with Brecon Pharma Consulting LLC since December 2012. Since August 2020, Dr. Dalesandro has served as an independent director on the board
S-8
EX-23.1
SEEL
Seelos Therapeutics Inc
6 Mar 24
Registration of securities for employees
5:38pm
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the use of our report dated March 6, 2024, with respect
S-8
SEEL
Seelos Therapeutics Inc
6 Mar 24
Registration of securities for employees
5:38pm
on August 11, 2014).
5.1
Opinion of Brownstein Hyatt Farber Schreck, LLP.
23.1
Consent of KPMG LLP, Independent Registered Public Accounting Firm.
23.2
S-8
EX-5.1
SEEL
Seelos Therapeutics Inc
6 Mar 24
Registration of securities for employees
5:38pm
without independent verification that (i) each natural person executing any of the documents we reviewed has sufficient legal capacity to do so; (ii
8-K
EX-4.1
n82zz79d 9xedm1yzis7
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.2
grrwkh 08n0ml56jx7
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
3qv3fuu06
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-5.1
d62je 7lv9sg
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
424B5
70qnb
30 Jan 24
Prospectus supplement for primary offering
6:05am
DEFA14A
vn61ow0774fah8jy4i7f
2 Jan 24
Additional proxy soliciting materials
8:10am